Schwarz and Mylan settle omeprazole dispute
Executive Summary
Schwarz' Kremers Urban Development Company will pay Mylan and its development partner, Spain-based Esteve Quimica, $50 mil. under June 25 agreement to settle lawsuits related to generic omeprazole (1"The Pink Sheet" Aug. 11, 2003, p. 11). Mylan will receive $37.5 mil and Esteve Quimica will receive $12.5 mil...
You may also be interested in...
Mylan Launches Generic Omeprazole; Takes Risk For Purple Gold
Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.